Your browser doesn't support javascript.
loading
Outcomes of older adults aged 90 and over with cutaneous malignancies after electrochemotherapy with bleomycin: A matched cohort analysis from the InspECT registry.
Sersa, Gregor; Mascherini, Matteo; Di Prata, Claudia; Odili, Joy; de Terlizzi, Francesca; McKenzie, Gordon A G; Clover, A James P; Bertino, Giulia; Spina, Romina; Groselj, Ales; Cappellesso, Rocco; Gehl, Julie; Bisase, Brian; Curatolo, Pietro; Kis, Erika; Lico, Valbona; Muir, Tobian; Orlando, Antonio; Quaglino, Pietro; Matteucci, Paolo; Valpione, Sara; Campana, Luca G.
Afiliación
  • Sersa G; Institute of Oncology Ljubljana, Department of Experimental Oncology, Zaloska 2, SI-1000, Ljubljana, Slovenia; University of Ljubljana, Faculty of Health Sciences, Zdravstvena Pot 5, SI-1000, Ljubljana, Slovenia. Electronic address: gsersa@onko-i.si.
  • Mascherini M; Clinica Chirurgica-1, Ospedale Policlinico San Martino, University of Genova, Italy. Electronic address: mascherinimatteo@gmail.com.
  • Di Prata C; University of Padua School of Surgery, Padua, Italy. Electronic address: claudia.diprata.md@gmail.com.
  • Odili J; Department of Plastic Surgery, St George's Hospital, London, United Kingdom. Electronic address: joy.odili@virginmedia.com.
  • de Terlizzi F; Scientific & Medical Department, IGEA S.p.A, Via Parmenide 10/A, 41012, Carpi, Mo, Italy. Electronic address: f.deterlizzi@igeamedical.com.
  • McKenzie GAG; Wolfson Palliative Care Research Centre, Hull York Medical School, Allam Medical Building, University of Hull, Hull HU6 7RX, United Kingdom. Electronic address: Gordon.McKenzie@hey.nhs.uk.
  • Clover AJP; Department of Plastic Surgery, Cork University Hospital and Cancer Research@UCC, University College Cork, Cork, Ireland. Electronic address: j.clover@ucc.ie.
  • Bertino G; Department of Otorhinolaryngology, University of Pavia, IRCCS Policlinico San Matteo Foundation, 27100, Pavia, Italy. Electronic address: giulia.bertino68@gmail.com.
  • Spina R; Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. Electronic address: romina.spina@iov.veneto.it.
  • Groselj A; Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Zaloska 2, SI-1000, Ljubljana, Slovenia; University of Ljubljana, Faculty of Medicine, Vrazov trg 2, SI-1000, Ljubljana, Slovenia. Electronic address: ales.groselj@kclj.si.
  • Cappellesso R; Pathological Anatomy Unit, Padua University Hospital, Padua, 35121, Italy. Electronic address: rocco.cappellesso@gmail.com.
  • Gehl J; Center for Experimental Drug and Gene Electrotransfer (C∗EDGE), Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Køge, Denmark; Faculty of Health and Medical Sciences, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Electronic ad
  • Bisase B; Clinic for Head & Neck Cancer, Queen Victoria Hospital NHS Foundation Trust, West Sussex, United Kingdom. Electronic address: brian.bisase@nhs.net.
  • Curatolo P; Department of Internal Medicine and Medical Specialties - Division of Dermatology, University "La Sapienza", Rome, Italy. Electronic address: pietro.curatolo@uniroma1.it.
  • Kis E; Department of Dermatology and Allergology, University of Szeged, Hungary. Electronic address: ksgbrll@gmail.com.
  • Lico V; Chirurgia Generale ULSS 3, Serenissima, Mirano, Italy. Electronic address: valbona.lico@aulss3.veneto.it.
  • Muir T; James Cook University Hospital, Middlesbrough, United Kingdom. Electronic address: tobian.muir@nhs.net.
  • Orlando A; Department of Plastic and Reconstructive Surgery, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom. Electronic address: antonio.orlando@nbt.nhs.uk.
  • Quaglino P; Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Turin, Italy. Electronic address: pietro.quaglino@unito.it.
  • Matteucci P; Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom. Electronic address: paolo.matteucci@hey.nhs.uk.
  • Valpione S; Cancer Research UK, The University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom. Electronic address: sara.valpione@cruk.manchester.ac.uk.
  • Campana LG; Department of Surgical Oncological and Gastroenterological Sciences (DISCOG), University of Padua, Padua, Italy; The Christie NHS Foundation Trust, Manchester, United Kingdom. Electronic address: luca.campana@nhs.net.
Eur J Surg Oncol ; 47(4): 902-912, 2021 04.
Article en En | MEDLINE | ID: mdl-33183930
BACKGROUND: With extending life expectancy, more people are diagnosed with cutaneous malignancies at advanced ages and are offered nonsurgical treatment. We assessed outcomes of the oldest-old adults after electrochemotherapy (ECT). METHODS: The International Network for Sharing Practices of ECT (InspECT) registry was queried for adults aged ≥90 years (ys) with skin cancers/cutaneous metastases of any histotype who underwent bleomycin-ECT (2006-2019). These were subanalysed with patients aged <90 ys after matching 1:2 for tumor location, number, size, histotype, and previous treatments. We assessed ECT modalities, toxicity (CTCAE), response (RECIST), and patient perception (EQ-5D). RESULTS: Sixty-one patients represented the study cohort (median 92 ys, range 92-104), 122 the control group (median 77 ys, range 23-89). Among the oldest-old, 44 patients (72%) had primary/recurrent skin cancers, 17 (28%) cutaneous metastases. Median tumour size was 15 mm (range, 5-450). The oldest-old adults underwent ECT mainly under local/regional anaesthesia (59% vs 39% p = .012). We observed no differences regarding dose and route of chemotherapy (intravenous vs intratumoral, p = .308), electrode geometry (linear vs hexagonal, p = .172) and procedural duration (18 vs 21 min, p = .378). Complete response (57.4 [95%-CI 44.1%-70.0%] vs 64.7% [95%-CI 55.6%-73.2%], p = .222) and 1-year local control (76.7% vs 81.7, p = .092) rates were comparable. Pain and skin hyperpigmentation were mild in both groups. Skin ulceration persisted longer in the oldest-old patients (4.4 vs 2.4 months, p = .008). CONCLUSIONS: The oldest-old adults with cutaneous malignancies undergo ECT most commonly under local/regional anaesthesia with safety profiles and clinical effectiveness similar to their younger counterparts, except in case of ulcerated tumors.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Bleomicina / Electroquimioterapia / Antibióticos Antineoplásicos / Recurrencia Local de Neoplasia Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Bleomicina / Electroquimioterapia / Antibióticos Antineoplásicos / Recurrencia Local de Neoplasia Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido